Taysha Gene Therapies, Inc. — 2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual filing; it does not provide a standalone fourth-quarter income statement or cash-flow summary. The 2019 comparison covers only the period from the company’s September 20, 2019 inception through year-end, so it is not a full-year comparable period.
Business context
Taysha is a clinical-stage gene therapy company developing AAV-based treatments for monogenic central nervous system diseases. It reported no approved products and no product sales. Its strategy relies on a research and development partnership with UT Southwestern, with a pipeline focused on neurodegenerative diseases, neurodevelopmental disorders and genetic epilepsies. The filing describes a broad portfolio, but gives inconsistent counts: 25 candidates in parts of the Business section and 19 in MD&A.
Key financial metrics
| Metric | FY 2020 | 2019 inception period |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $31.9 million | $1.0 million |
| General and administrative expense | $11.1 million | $0.1 million |
| Operating loss | $43.0 million | $1.1 million |
| Net loss | $60.0 million | $1.1 million |
| Net loss per share, basic and diluted | $3.40 | $0.12 |
| Net cash used in operating activities | $30.7 million | $0 |
| Net cash used in investing activities | $9.1 million | $0 |
| Net cash provided by financing activities | $291.1 million | $0 |
At December 31, 2020, cash and cash equivalents were $251.3 million; total assets were $258.9 million, total liabilities $7.6 million and stockholders’ equity $251.3 million. Current assets were $257.9 million versus current liabilities of $7.1 million. The balance sheet reported no outstanding debt. Lease commitments totaled $23.3 million, primarily for the planned Durham manufacturing facility. Management estimated existing cash would fund operating expenses and capital requirements into 2023, subject to assumptions and risks.
No gross margin or operating margin is meaningful because the company had no revenue. The $60.0 million net loss included a $17.0 million non-cash expense from remeasuring a preferred-stock tranche liability. R&D expense rose substantially as the company licensed programs and expanded research, manufacturing and clinical-preparation work.
Material changes and financing
- The company raised approximately $307.0 million gross through Series A and Series B preferred-stock financings and its September 2020 IPO. The IPO generated $181.0 million gross and $165.9 million net proceeds.
- Series A and Series B preferred shares converted into common stock upon the IPO. Year-end common shares outstanding were 37.8 million; 4.3 million potentially dilutive awards were excluded from diluted loss per share as anti-dilutive.
- Operating cash use was $30.7 million, while the reported net loss was $60.0 million; the difference principally reflects non-cash items and changes in working capital. The company also paid $9.0 million for research and development licenses, reported as investing cash outflow.
- The audited financial statements received an unqualified opinion. The auditor did not audit or express an opinion on internal control effectiveness; the company reported effective disclosure controls and was exempt from auditor attestation as a newly public emerging growth company.
Outlook, commentary and principal risks
Management planned to advance its clinical and preclinical programs and expand manufacturing capacity. At filing, the TSHA-101 Phase 1/2 trial had been initiated in Canada under a Health Canada CTA; preliminary safety and biomarker data were expected in the second half of 2021, with preliminary clinical data expected by year-end 2021. The company planned U.S. IND and trial initiation for TSHA-101, submissions for TSHA-102 and TSHA-104, and a TSHA-118 Phase 1/2 trial in 2021. These are forward-looking plans, not financial guidance or assured outcomes.
- The company expects continued significant losses and substantial R&D investment, with additional financing likely needed beyond its stated cash runway. It has never generated product revenue and may never achieve profitability.
- All programs remain early-stage; positive preclinical results may not predict clinical safety or efficacy. Gene therapy and intrathecal delivery have risks including immune responses, toxicity, manufacturing challenges and evolving regulatory requirements.
- Execution depends heavily on UT Southwestern for discovery, preclinical work and IND-enabling studies, and on third parties for manufacturing and clinical operations. Patient identification and enrollment, supply constraints and COVID-19 disruptions could delay development.
- The company disclosed a 2020 letter from REGENXBIO concerning patents related to AAV9 vectors and a possible license. It stated that commercialization before relevant patents expire in 2026 without a license could prompt an infringement claim.
- COVID-19 had not materially affected 2020 financial results or operations according to management, but future effects on trials, supply, financing and timelines remained uncertain.
- There were no material legal proceedings reported. No cash dividends had been paid or were expected in the foreseeable future.
Most important facts for investors to verify
- Whether the stated cash runway into 2023 remains reasonable against actual quarterly cash burn, trial costs, facility spending and financing needs.
- Clinical-trial progress, safety, biomarker and efficacy data for TSHA-101 and subsequent progress for TSHA-118, TSHA-102 and TSHA-104.
- The status and potential cost or restrictions associated with the AAV9 patent matter raised by REGENXBIO.
- Construction, cost, timing and qualification of the Durham manufacturing facility, and the company’s dependence on UT Southwestern and other suppliers.
- The pipeline-count inconsistency in the filing and the current development stage and prioritization of each program.
- Potential dilution from equity awards, future capital raises and the company’s disclosed related-party arrangements.